Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.2	0.26	0.12	3.1	0.7	1.12
Revenue Growth (YoY)	38.08%	111.03%	-96.02%	343.92%	-37.79%	-72.22%
Gross Profit	0.2	0.26	0.12	3.1	0.7	1.12
Selling, General & Admin	6.84	6.73	6.22	6.51	2.62	4.27
Research & Development	13.52	13.62	12.03	11.36	0.89	2.55
Operating Expenses	20.35	20.35	18.25	17.87	3.52	6.82
Operating Income	-20.16	-20.09	-18.13	-14.77	-2.82	-5.7
Interest Expense / Income	-0.42	0	0	0.02	0.03	0.02
Other Expense / Income	-0.53	-1.06	-0.07	-	-	-
Pretax Income	-19.2	-19.03	-18.05	-14.79	-2.85	-5.72
Net Income	-19.2	-19.03	-18.05	-14.79	-2.85	-5.72
Shares Outstanding (Basic)	6	5	4	3	1	1
Shares Outstanding (Diluted)	6	5	4	3	1	1
Shares Change	38.29%	26.28%	39.15%	121.72%	0.39%	2.08%
EPS (Basic)	-3.34	-3.57	-4.28	-4.86	-2.10	-4.20
EPS (Diluted)	-3.34	-3.57	-4.28	-4.86	-2.10	-4.20
Free Cash Flow	-15.99	-18.1	-17.59	-14.3	-1.13	-0.34
Free Cash Flow Per Share	-2.52	-3.39	-4.17	-4.71	-0.82	-0.25
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-10285.34%	-7711.98%	-14686.17%	-476.23%	-403.52%	-507.52%
Profit Margin	-9797.30%	-7304.73%	-14625.85%	-476.88%	-407.73%	-509.73%
Free Cash Flow Margin	-8161.12%	-6947.87%	-14253.37%	-461.11%	-161.69%	-30.13%
EBITDA	-19.45	-18.85	-18.05	-14.77	-2.82	-5.7
EBITDA Margin	-9922.57%	-7236.63%	-14620.41%	-476.23%	-403.52%	-507.52%
Depreciation & Amortization	0.18	0.18	0.01	0	0	0
EBIT	-19.63	-19.03	-18.05	-14.77	-2.82	-5.7
EBIT Margin	-10013.87%	-7304.73%	-14625.85%	-476.23%	-403.52%	-507.52%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).